Pubblicazioni
Pubblicazioni e Impact factor
Nel corso degli anni la produzione scientifica dei ricercatori dello IOV è molto cresciuta, collocando l’Istituto ai primi posti in Italia. Le pubblicazioni riferite al 2020 comunicate ufficialmente al Ministero della Salute sono aumentate del 25% rispetto all’anno precedente; una gran parte di esse ha trovato posto nelle riviste più prestigiose a livello mondiale. Anche l’IF normalizzato ha visto un notevole incremento, pari al 40% rispetto a quello dichiarato l’anno prima.
| Anno | N° pubblicazioni | IF normalizzato | IF per ricercatore | IF per ricercatore con pubblicazioni |
|---|---|---|---|---|
| 2020 | 352 | 1.764,86 | 5,77 | 10,59 |
| 2019 | 281 | 1.258,09 | 4,24 | 8,37 |
| 2018 | 256 | 1.219,14 | 7,85 | 8,58 |
| Titolo | autori | rivista | IF grezzo |
|---|---|---|---|
| Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma | Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni Vanna, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D. | The New England Journal of Medicine | 74.699 |
| Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer | Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno Laura, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. | The New England Journal of Medicine | 74.699 |
| Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte Pierfranco, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. | The New England Journal of Medicine | 74.699 |
| Cancer and COVID-19: what do we really know? | Poortmans,P. M., Guarneri Valentina, Cardoso,M. -J | Lancet | 60.392 |
| Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties | Panciera T, Citron A, Di Biagio D, Battilana G, Gandin A, Giulitti S, Forcato M, Bicciato S, Panzetta V, Fusco S, Azzolin L, Totaro A, Dei Tos AP, Fassan M, Vindigni V, Bassetto F, Rosato Antonio, Brusatin G, Cordenonsi M, Piccolo S. | Nature Materials | 38.663 |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | Prat,A., Guarneri Valentina, Parè,L., Griguolo Gaia, Pascual,T., Dieci Maria Vittoria, Chic,N., Gonzalez-Farrè,B., Frassoldati,A., Sanfeliu,E., Cejalvo,J. M., Munoz,M., Bisagni,G., Braso-Maristany,F., Urso,L., Vidal,M., Brandes,A. A., Adamo,B., Musolino,A., MIGLIETTA FEDERICA (…) | Lancet Oncology | 33.752 |
| A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors’ reply | Bisogno,G., Ferrari,A., Melcon,S. G., De Salvo Gian Luca, Bergeron,C., Jenney,M. | Lancet Oncology | 33.752 |
| Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial | Dummer,R., Brase,J. C., Garrett,J., Campbell,C. D., Gasal,E., Squires,M., Gusenleitner,D., Santinami,M., Atkinson,V., Mandalà ,M., Chiarion-Sileni Vanna, Flaherty,K., Larkin,J., Robert,C., Kefford,R., Kirkwood,J. M., Hauschild,A., Schadendorf,D., Long,G. V. | Lancet Oncology | 33.752 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial | Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni Vanna, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. | Lancet Oncology | 33.752 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study | Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello Giulia, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; TERAVOLT investigators. | Lancet Oncology | 33.752 |
| Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial | Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli Marco, Raut CP, Hompes D, De Paoli A, Sangalli C, Honoré C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litière S, Marreaud S, Gelderblom H, Haas RL. | Lancet Oncology | 33.752 |
| Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study | Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini Samantha, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Müller K, Gräfenstein L, Schulz C, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; EORTC Lung Cancer Group; European Society of Thoracic Surgeons. | Lancet Oncology | 33.752 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial | Cremolini C, Antoniotti C, Rossini D, Lonardi Sara, Loupakis Fotios, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni Sabina, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel Vittorina, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. | Lancet Oncology | 33.752 |
Fonte: Biblioteca scientifica IOV
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer | Group SOLAR-1 Study, André Fabrice, Ciruelos Eva, Rubovszky Gabor, Campone Mario, Loibl Sibylle, Rugo Hope S, Iwata Hiroji, Conte Pierfranco, Mayer Ingrid A, Kaufman Bella, Yamashita Toshinari, Lu Yen-Shen, Inoue Kenichi, Takahashi Masato, Pápai Zsuzsanna, Longin Anne-Sophie, Mills David, Wilke Celine, Hirawat Samit, Juric Dejan, Aieta Michele | NEW ENGLAND JOURNAL OF MEDICINE | 70.67 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer | Kopetz Scott, Grothey Axel, Yaeger Rona, Van Cutsem Eric, Desai Jayesh, Yoshino Takayuki, Wasan Harpreet, Ciardiello Fortunato, Loupakis Fotios, Hong Yong Sang, Steeghs Neeltje, Guren Tormod K, Arkenau Hendrik-Tobias, Garcia-Alfonso Pilar, Pfeiffer Per, Orlov Sergey, Lonardi Sara, Elez Elena, Kim Tae-Won, Schellens Jan H M, Guo Christina, Krishnan Asha, Dekervel Jeroen, Morris Van, Calvo Ferrandiz Aitana, Tarpgaard L S, Braun Michael, Gollerkeri Ashwin, Keir Christopher, Maharry Kati, Pickard Michael, Christy-Bittel Janna, Anderson Lisa, Sandor Victor, Tabernero Josep | NEW ENGLAND JOURNAL OF MEDICINE | 70.67 |
| Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma | Robert Caroline, Grob Jean J, Stroyakovskiy Daniil, Karaszewska Boguslawa, Hauschild Axel, Levchenko Evgeny, chiarion sileni vanna, Schachter Jacob, Garbe Claus, Bondarenko Igor, Gogas Helen, Mandalá Mario, Haanen John B A G, Lebbé Celeste, Mackiewicz Andrzej, Rutkowski Piotr, Nathan Paul D, Ribas Antoni, Davies Michael A, Flaherty Keith T, Burgess Paul, Tan Monique, Gasal Eduard, Voi Maurizio, Schadendorf Dirk, Long Georgina V | NEW ENGLAND JOURNAL OF MEDICINE | 70.67 |
| Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Larkin James, chiarion sileni vanna, Gonzalez Rene, Grob Jean-Jacques, Rutkowski Piotr, Lao Christopher D, Cowey C Lance, Schadendorf Dirk, Wagstaff John, Dummer Reinhard, Ferrucci Pier F, Smylie Michael, Hogg David, Hill Andrew, Márquez-Rodas Ivan, Haanen John, Guidoboni Massimo, Maio Michele, Schöffski Patrick, Carlino Matteo S, Lebbé Céleste, McArthur Grant, Ascierto Paolo A, Daniels Gregory A, Long Georgina V, Bastholt Lars, Rizzo Jasmine I, Balogh Agnes, Moshyk Andriy, Hodi F Stephen, Wolchok Jedd D | NEW ENGLAND JOURNAL OF MEDICINE | 70.67 |
| Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group | Hoeben Bianca A., Carrie Christian, Timmermann Beate, Mandeville Henry C., Gandola Lorenza, Dieckmann Karin, Ramos Albiac Monica, Magelssen Henriette, Lassen-Ramshad Yasmin, Ondrová Barbora, Ajithkumar Thankamma, Alapetite Claire, Balgobind Brian V., Bolle Stephanie, Cameron Alison L., Davila Fajardo Raquel, Dietzsch Stefan, Dumont Lecomte Delphine, van den Heuvel-Eibrink Marry M., Kortmann Rolf D., Laprie Anne, Melchior Patrick, Padovani Laetitia, Rombi Barbara, Scarzello Giovanni, Schwarz Rudolf, Seiersen Klaus, Seravalli Enrica, Thorp Nicola, Whitfield Gillian A., Boterberg Tom, Janssens Geert O. | LANCET ONCOLOGY | 35.386 |
| NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial | Bonvalot Sylvie, Rutkowski Piotr L., Thariat Juliette, Carrère Sébastien, Ducassou Anne, Sunyach Marie Pierre, Agoston P., Hong Angela, Mervoyer Augustin, Rastrelli Marco, Moreno Victor, Li Rubi K., Tiangco Béatrice, Herraez Antonio Casado, Gronchi Alessandro, Mangel László, Sy-Ortin Teresa, Hohenberger P., de Baère Thierry, Le Cesne Axel, Helfre Sylvie, Saada-Bouzid Esma, Borkowska A., Anghel Rodica, Co Ann, Gebhart Michael, Kantor Guy, Montero A., Loong Herbert H., Vergés Ramona, Lapeire Lore, Dema S., Kacso Gabriel, Austen Lyn, Moureau-Zabotto Laurence, Servois Vincent, Wardelmann Eva, Terrier Philippe, Lazar Alexander J., Bovée Judith V.M.G., Le Péchoux Cécile, Papai Zsusanna | LANCET ONCOLOGY | 35.386 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial | Fuchs Charles S., Shitara Kohei, Di Bartolomeo Maria, Lonardi Sara, Al-Batran Salah Eddin, Van Cutsem Eric, Ilson David H., Alsina Maria, Chau Ian, Lacy Jill, Ducreux Michel, Mendez Guillermo Ariel, Alavez Alejandro Molina, Takahari Daisuke, Mansoor Wasat, Enzinger Peter C., Gorbounova Vera, Wainberg Zev A., Hegewisch-Becker Susanna, Ferry David, Lin Ji, Carlesi Roberto, Das Mayukh, Shah Manish A., Luft Alexander V., Karaseva Nina A., Kowalyszyn Rubén Dario, Hernandez Carlos Alberto, Csoszi Tibor, De Vita Ferdinando, Pfeiffer Per, Sugimoto Naotoshi, Kocsis Judit, Csilla Andràs, Bodoky Gyorgy, Garnica Jaliffe Georgina, Protsenko Svetlana, Madi Ayman, Wojcik Elzbieta, Brenner Baruch, Folprecht Gunnar, Sarosiek Tomasz, Peltola Katriina Johanna, Bono Peter, Ayala Hubert, Aprile Giuseppe, Gerardo Cardellino Giovanni, Huitzil Melendez Fidel David, Falcone Alfredo, Di Costanzo Francesco, Group RAINFALL Study | LANCET ONCOLOGY | 35.386 |
| Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) | Schadendorf Dirk, Hauschild Axel, Santinami Mario, Atkinson Victoria, Mandalà Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Lesimple Thierry, Plummer Ruth, Schachter Jacob, Dasgupta Kohinoor, Manson Stephanie, Koruth Roy, Mookerjee Bijoyesh, Kefford Richard, Dummer Reinhard, Kirkwood John M., Long Georgina V. | LANCET ONCOLOGY | 35.386 |
| Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers | Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci Maria Vittoria, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotirou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S | JOURNAL OF CLINICAL ONCOLOGY | 28.349 |
| Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial | Lebbé Celeste, Meyer Nicolas, Mortier Laurent, Marquez-Rodas Ivan, Robert Caroline, Rutkowski Piotr, Menzies Alexander M, Eigentler Thomas, Ascierto Paolo A, Smylie Michael, Schadendorf Dirk, Ajaz Mazhar, Svane Inge Marie, Gonzalez Rene, Rollin Linda, Lord-Bessen Jennifer, Saci Abdel, Grigoryeva Elena, Pigozzo Jacopo | JOURNAL OF CLINICAL ONCOLOGY | 28.349 |
| Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group | Group on behalf of the EpSSG Radiology, Vaarwerk Bas, Bisogno Gianni, McHugh Kieran, Brisse Hervé J., Morosi Carlo, Corradini Nadège, Jenney Meriel, Orbach Daniel, Chisholm Julia C., Ferrari Andrea, Zanetti Ilaria, De Salvo Gian Luca, van Rijn Rick R., Merks Johannes H.M. | JOURNAL OF CLINICAL ONCOLOGY | 28.349 |
| Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study | Draaisma Kaspar, Chatzipli Aikaterini, Taphoorn Martin, Kerkhof Melissa, Weyerbrock Astrid, Sanson Marc, Hoeben Ann, Lukacova Slávka, Lombardi Giuseppe, Leenstra Sieger, Hanse Monique, Fleischeuer Ruth, Watts Colin, McAbee Joseph, Angelopoulos Nicos, Gorlia Thierry, Golfinopoulos Vassilis, Kros Johan M, Verhaak Roel G W, Bours Vincent, van den Bent Martin J, McDermott Ultan, Robe Pierre A, French Pim J | JOURNAL OF CLINICAL ONCOLOGY | 28.349 |
| Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy | Morano Federica, Corallo Salvatore, Lonardi Sara, Raimondi Alessandra, Cremolini Chiara, Rimassa Lorenza, Murialdo Roberto, Zaniboni Alberto, Sartore-Bianchi Andrea, Tomasello Gianluca, Racca Patrizia, Clavarezza Matteo, Adamo Vincenzo, Perrone Federica, Gloghini Annunziata, Tamborini Elena, Busico Adele, Martinetti Antonia, Palermo Federica, Loupakis Fotios, Milione Massimo, Fucà Giovanni, Di Bartolomeo Maria, de Braud Filippo, Pietrantonio Filippo | JOURNAL OF CLINICAL ONCOLOGY | 28.349 |
| Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results | Sharma Padmanee, Siefker-Radtke Arlene, de Braud Filippo, Basso Umberto, Calvo Emiliano, Bono Petri, Morse Michael A, Ascierto Paolo A, Lopez-Martin Jose, Brossart Peter, Rohrberg Kristoffer, Mellado Begoña, Fischer Bruce S, Meadows-Shropshire Stephanie, Abdel Saci , Callahan Margaret K, Rosenberg Jonathan | JOURNAL OF CLINICAL ONCOLOGY | 28.349 |
| Reply to E. Hindié and K.R. Hess | Long Georgina V, Dummer Reinhard, Schadendorf Dirk, Santinami Mario, Atkinson Victoria, Mandalà Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Haas Tomas, Shilkrut Mark, Gasal Eduard, Kefford Richard, Kirkwood John M, Hauschild Axel | JOURNAL OF CLINICAL ONCOLOGY | 28.349 |
Fonte: Biblioteca scientifica IOV
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Cabozantinib in patients with advanced and progressing hepatocellular carcinoma | Abou-Alfa Ghassan K., Meyer Tim, Cheng Ann Lii, El-Khoueiry Anthony B., Rimassa Lorenza, Ryoo Baek Yeol, Cicin Irfan, Merle Philippe, Chen Yen Hsun, Park Joong Won, Blanc Jean Frederic, Bolondi Luigi, Kl¿¿mpen Heinz Josef, Chan Stephen L., zagonel vittorina, Pressiani Tiziana, Ryu Min Hee, Venook Alan P., Hessel Colin, Borgman-Hagey Anne E., Schwab Gisela, Kelley Robin K. | NEW ENGLAND JOURNAL OF MEDICINE | 79.26 |
| Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial | Group European paediatric Soft tissue sarcoma Study, Bisogno Gianni, Jenney Meriel, Bergeron Christophe, Gallego Melc¿¿n Soledad, Ferrari Andrea, Oberlin Odile, Carli Modesto, Stevens Michael, Kelsey Anna, De Paoli Angela, Gaze Mark N, Martelli Helene, Devalck Christine, Merks Johannes H, Ben-Arush Myriam, Glosli Heidi, Chisholm Julia, Orbach Daniel, Minard-Colin Veronique, De Salvo Gian Luca | LANCET ONCOLOGY | 36.421 |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) a multicentre, open-label, randomised phase 3 trial | Dummer Reinhard, Ascierto Paolo A, Gogas Helen J, Arance Ana, Mandala Mario, Liszkay Gabriella, Garbe Claus, Schadendorf Dirk, Krajsova Ivana, Gutzmer Ralf, chiarion sileni vanna, Dutriaux Caroline, de Groot Jan Willem B, Yamazaki Naoya, Loquai Carmen, Moutouh-de Parseval Laure A, Pickard Michael D, Sandor Victor, Robert Caroline, Flaherty Keith T | LANCET ONCOLOGY | 36.421 |
| Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21) a placebo-controlled, phase 3 randomised trial | Friedlander Michael, Gebski Val, Gibbs Emma, Davies Lucy, Bloomfield Ralph, Hilpert Felix, Wenzel Lari B., Eek Daniel, Rodrigues Manuel, Clamp Andrew, Penson Richard T., Provencher Diane, Korach Jacob, Huzarski Tomasz, Vidal Laura, Salutari Vanda, Scott Clare, NICOLETTO MARIA ORNELLA, Tamura Kenji, Espinoza David, Joly Florence, Pujade-Lauraine Eric | LANCET ONCOLOGY | 36.421 |
| Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) 4-year outcomes of a multicentre, randomised, phase 3 trial | Hodi Frank Stephen, chiarion sileni vanna, Gonzalez Rene, Grob Jean-Jacques, Rutkowski Piotr, Cowey Charles Lance, Lao Christopher D, Schadendorf Dirk, Wagstaff John, Dummer Reinhard, Ferrucci Pier Francesco, Smylie Michael, Hill Andrew, Hogg David, Marquez-Rodas Ivan, Jiang Joel, Rizzo Jasmine, Larkin James, Wolchok Jedd D | LANCET ONCOLOGY | 36.421 |
| Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial | Dummer R., Ascierto P.A., Gogas H.J., Arance A., Mandala M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., chiarion sileni vanna, Dutriaux C., de Groot J.W.B., Yamazaki N., Loquai C., Moutouh-de Parseval L.A., Pickard M.D., Sandor V., Robert C., Flaherty K.T. | LANCET ONCOLOGY | 36.421 |
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224) a non-randomised, open-label phase 2 trial | KEYNOTE-224 investigators Gruppo, Zhu Andrew X, Finn Richard S, Edeline Julien, Cattan Stephane, Ogasawara Sadahisa, Palmer Daniel, Verslype Chris, zagonel vittorina, Fartoux Laetitia, Vogel Arndt, Sarker Debashis, Verset Gontran, Chan Stephen L, Knox Jennifer, Daniele Bruno, Webber Andrea L, Ebbinghaus Scot W, Ma Junshui, Siegel Abby B, Cheng Ann-Lii, Kudo Masatoshi | LANCET ONCOLOGY | 36.421 |
| Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA) a multicentre, open-label, randomised, controlled, phase 2 trial | LOMBARDI GIUSEPPE, De Salvo Gian Luca, Brandes Alba Ariela, Eoli Marica, Rud¿¿ Roberta, Faedi Marina, Lolli Ivan, Pace Andrea, Daniele Bruno, Pasqualetti Francesco, Rizzato Simona, Bellu Luisa, Pambuku Ardi, Farina Miriam, Magni Giovanna, Indraccolo Stefano, Gardiman Marina Paola, Soffietti Riccardo, zagonel vittorina | LANCET ONCOLOGY | 36.421 |
| Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC) a final analysis of a phase 3, randomised, placebo-controlled study | Rimassa Lorenza, Assenat Eric, Peck-Radosavljevic Markus, Pracht Marc, zagonel vittorina, Mathurin Philippe, Rota Caremoli Elena, Porta Camillo, Daniele Bruno, Bolondi Luigi, Mazzaferro Vincenzo, Harris William, Damjanov Nevena, Pastorelli Davide, Reig Mar¿¿a, Knox Jennifer, Negri Francesca, Trojan J¿¿rg, L¿¿pez L¿¿pez Carlos, Personeni Nicola, Decaens Thomas, Dupuy Marie, Sieghart Wolfgang, Abbadessa Giovanni, Schwartz Brian, Lamar Maria, Goldberg Terri, Shuster Dale, Santoro Armando, Bruix Jordi | LANCET ONCOLOGY | 36.421 |
| Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: Joint analysis of MILES-3 and MILES-4 phase III trials | Gridelli C., Morabito A., Cavanna L., Luciani A., Maione P., Bonanno Laura, Filipazzi V., Leo S., Cinieri S., Ciardiello F., Burgio M.A., Bilancia D., Cortinovis D., Rosetti F., Bianco R., Gebbia V., Artioli F., Bordonaro R., Fregoni V., Mencoboni M., Nelli F., Riccardi F., Di Isernia G., Costanzo R., Rocco G., Daniele G., Signoriello S., Piccirillo M.C., Gallo C., Perrone F. | JOURNAL OF CLINICAL ONCOLOGY | 26.36 |
| BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer | Wang Fei, Zhao Shihua, Shen Xiaopei, Zhu Guangwu, Liu Rengyun, Viola David, Elisei Rossella, Puxeddu Efisio, Fugazzola Laura, Colombo Carla, Jarzab Barbara, Czarniecka Agnieszka, Lam Alfred K, Mian Caterina, Vianello Federica, Yip Linwah, Riesco-Eizaguirre Garcilaso, Santisteban Pilar, O’Neill Christine J, Sywak Mark S, Clifton-Bligh Roderick, Bendlova Bela, S¿¿korov¿¿ Vlasta, Wang Yangang, Xing Mingzhao | JOURNAL OF CLINICAL ONCOLOGY | 26.36 |
| Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups | Walterhouse David O, Barkauskas Donald A, Hall David, Ferrari Andrea, De Salvo Gian Luca, Koscielniak Ewa, Stevens Michael C G, Martelli H¿¿l¿¿ne, Seitz Guido, Rodeberg David A, Shnorhavorian Margarett, Dasgupta Roshni, Breneman John C, Anderson James R, Bergeron Christophe, Bisogno Gianni, Meyer William H, Hawkins Douglas S, Minard-Colin Veronique | JOURNAL OF CLINICAL ONCOLOGY | 26.36 |
| Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | Overman Michael J, Lonardi Sara, Wong Ka Yeung Mark, Lenz Heinz-Josef, Gelsomino Fabio, Aglietta Massimo, Morse Michael A, Van Cutsem Eric, McDermott Ray, Hill Andrew, Sawyer Michael B, Hendlisz Alain, Neyns Bart, Svrcek Magali, Moss Rebecca A, Ledeine Jean-Marie, Cao Z Alexander, Kamble Shital, Kopetz Scott, Andr¿¿ Thierry | JOURNAL OF CLINICAL ONCOLOGY | 26.36 |
| FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial | Investigators TOSCA, Sobrero Alberto, Lonardi Sara, Rosati Gerardo, Di Bartolomeo Maria, Ronzoni Monica, Pella Nicoletta, Scartozzi Mario, Banzi Maria, Zampino Maria Giulia, Pasini Felice, Marchetti Paolo, Cantore Maurizio, Zaniboni Alberto, Rimassa Lorenza, Ciuffreda Libero, Ferrari Daris, zagonel vittorina, Maiello Evaristo, Barni Sandro, Rulli Eliana, Labianca Roberto | JOURNAL OF CLINICAL ONCOLOGY | 26.36 |
| Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma | Hauschild Axel, Dummer Reinhard, Schadendorf Dirk, Santinami Mario, Atkinson Victoria, Mandal¿¿ Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Haas Tomas, Shilkrut Mark, Gasal Eduard, Kefford Richard, Kirkwood John M, Long Georgina V | JOURNAL OF CLINICAL ONCOLOGY | 26.36 |
Fonte: Biblioteca scientifica IOV
I dati pubblicati in questa pagina sono forniti dalla Biblioteca scientifica IOV.
Last modified: 30/04/2021 14:57